Skip to main content

Patent Ductus Arteriosus

0
Pipeline Programs
5
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 7 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
3 programs
ADO II ASN/A1 trial
AMPLATZER Duct Occluder IIN/A1 trial
Amplatzer Piccolo OccluderN/A1 trial
Active Trials
NCT03055858Completed200Est. Apr 2022
NCT00713700Completed192Est. Oct 2016
NCT04371081Active Not Recruiting70Est. Jul 2027
Lundbeck
LundbeckDenmark - Copenhagen
3 programs
Early ibuprofenN/ASmall Molecule1 trial
INVOS Cerebral/Somatic oximeterN/A1 trial
IbuprofenN/ASmall Molecule1 trial
Active Trials
NCT00802685Terminated105Est. Feb 2011
NCT00554307Withdrawn0Est. Dec 2009
NCT00833365Terminated15Est. Nov 2011
Occlutech
OcclutechSwitzerland - Schaffhausen
2 programs
Occlutech PDA occluderN/A1 trial
Occlutech® PDA OccluderN/A1 trial
Active Trials
NCT01479218Completed50Est. May 2014
NCT05264753Recruiting255Est. Nov 2029
Cook Medical
Cook MedicalIN - Bloomington
1 program
IbuprofenN/ASmall Molecule1 trial
Active Trials
NCT01758913Completed110Est. Feb 2012
Pediatrix Therapeutics
Pediatrix TherapeuticsChina - Shanghai
1 program
PDA Post NICU DischargeN/A1 trial
Active Trials
NCT02750228Completed208Est. Jun 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
OcclutechOcclutech® PDA Occluder
AbbottAmplatzer Piccolo Occluder
AbbottADO II AS
Pediatrix TherapeuticsPDA Post NICU Discharge
OcclutechOcclutech PDA occluder
LundbeckIbuprofen
AbbottAMPLATZER Duct Occluder II
LundbeckEarly ibuprofen
LundbeckINVOS Cerebral/Somatic oximeter
Cook MedicalIbuprofen

Clinical Trials (10)

Total enrollment: 1,205 patients across 10 trials

NCT05264753OcclutechOcclutech® PDA Occluder

Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects

Start: Dec 2021Est. completion: Nov 2029255 patients
N/ARecruiting
NCT04371081AbbottAmplatzer Piccolo Occluder

Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance

Start: Apr 2020Est. completion: Jul 202770 patients
N/AActive Not Recruiting
NCT03055858AbbottADO II AS

AMPLATZER Duct Occluder II Additional Sizes

Start: Jun 2017Est. completion: Apr 2022200 patients
N/ACompleted
NCT02750228Pediatrix TherapeuticsPDA Post NICU Discharge

PDA Post NICU Discharge

Start: May 2016Est. completion: Jun 2020208 patients
N/ACompleted
NCT01479218OcclutechOcclutech PDA occluder

Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus

Start: Nov 2011Est. completion: May 201450 patients
N/ACompleted
NCT00833365LundbeckIbuprofen

Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure

Start: Jan 2009Est. completion: Nov 201115 patients
N/ATerminated
NCT00713700AbbottAMPLATZER Duct Occluder II

AMPLATZER Duct Occluder II Clinical Study

Start: Aug 2008Est. completion: Oct 2016192 patients
N/ACompleted
NCT00802685LundbeckEarly ibuprofen

Timing of PDA Closure and Respiratory Outcome in Premature Infants

Start: Nov 2007Est. completion: Feb 2011105 patients
N/ATerminated
NCT00554307LundbeckINVOS Cerebral/Somatic oximeter

Brain, Gut and Kidney Blood Flow During Medical Closure of PDA

Start: Nov 2007Est. completion: Dec 20090
N/AWithdrawn
NCT01758913Cook MedicalIbuprofen

Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants

Start: Feb 2007Est. completion: Feb 2012110 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,205 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.